Immunicon Corp. has entered into a research services agreement with Bristol-Myers Squibb (BMS) involving protein and molecular targets associated with circulating tumor cells (CTCs). Leon Terstappen, M.D., Ph.D., chief scientific officer of Immunicon said, “The list of pharmaceutical partners and biomarkers continues to expand. Our collaborations span across protein biomarkers, phosphoproteins and a variety of FISH assays to study gene amplification in a number of different carcinomas...